In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Kirsten rat sarcoma virus (KRAS) gene tests are carried out to detect gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including colorectal cancer, certain lung cancers and some leukemias. GlobalData uses proprietary data and analytics to provide a comprehensive report on the kras tests devices market, including market shares of different players within New Zealand. Buy the latest report here.
Smarter leaders trust GlobalData
In 2022, GlobalData’s Market Model methodology determined that the leading player in the kras tests market in New Zealand was Qiagen followed by F. Hoffmann-La Roche, Sysmex and Biocartis Group.
Colorectal cancer (CRC) is classified based on the stage of the disease at diagnosis. CRC has been divided into localized, regional metastasis, and distant metastasis. Localized CRC is defined as cancer that has not yet metastasized. Regional metastasis refers to cancer that has spread to the lymph nodes near the colon or rectum. Distant metastasis refers to cancer that has spread to other organs of the body such as the lungs. There are two other widely used systems to classify CRC. The first groups CRC into stages -IV and the second use a lettering system (A-D). GlobalData considers stage -II & A-B as localized, stage III & stage C as regional metastasis, and stage IV & stage D as distant metastasis. The KRAS Tests market includes Colorectal Cancer Stages of Diagnosis, Sanger Sequencing Tests; Nucleic Acid Amplification Tests (NAATs), and Other KRAS Tests.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the kras tests devices market within New Zealand was expected to be over $0.09m in 2022.
For the latest complete market share analysis of kras tests device market in New Zealand, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
